Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

In this issue

Insight

Close up of a person sticking their tongue out with lots of pills in their moth

We need to reassess how we measure and treat pain as opioid addiction growsSubscription

By

Removing official pain measures will not alleviate the rising number of patients addicted to opioid drugs — a better way to determine pain is required.

CPD article

X-ray of the intestines of a patient with Crohn's disease

Biosimilars and inflammatory bowel disease: a switch programme using CT-P13Subscription

By

How to plan and manage switching patients from a biologic to a biosimilar in inflammatory bowel disease, using the University Hospital Southampton NHS Foundation Trust’s experience as an example.

Review

Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary syndromes.

Cardiovascular side effects of cancer treatmentsSubscription

By , ,

The cardiovascular side effects of cancer treatments remain a challenge in oncologic care. Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary events. The treatments most frequently associated with cardiovascular side effects include anthracyclines, monoclonal antibodies (mAbs) targeting the HER2 pathway, and small molecule tyrosine kinase inhibitors (TKIs), ...

Research Article

Oral anticoagulant therapy and INR blood test monitor

Assessing the impact of a targeted pharmacist-led anticoagulant review clinicSubscription

By , , ,

Local guidance, supported by the 2014 National Institute for Health and Care Excellence (NICE) guideline CG180 for atrial fibrillation (AF), recommends that patients receiving inadequate anticoagulation with a vitamin K antagonist (VKA), including time in therapeutic range (TTR) of <65%, should be reassessed. These patients were identified by the anticoagulation monitoring service (AMS) and highlighted to GPs for review. However, up to 59.3% of patients received ...

Short Communications

Improving the care of people with learning disabilities in pharmacySubscription

By

There are about 1.2 million people in England with a learning disability. A number of recent studies have ...

Talk about medicines week Subscription

By ,

We are writing to share with you our learning and experience on an annual patient and multidisciplinary education event.

NHS England tried hard to manage funding of new hepatitis C drugsSubscription

By

I read with interest the letter from Charles Gore of The Hepatitis C Trust asking why NHS England is treating people living with hepatitis C as exceptional cases and has capped the access to medicines that can eradicate the infection in most cases.

Pharmaceutical Journal Jobs

More jobs

Clinical Pharmacist

CP September 2016, Vol 8, No 9

Cover Story:

Impact of a pharmacist-led anticoagulant review clinic

Read more…

Clinical Pharmacist

View previous issue

Clinical Pharmacist is a monthly, peer-reviewed journal that provides authoritative resources on the clinical management of disease in relation to medicines and up-to-date information about advances in pharmacy and drug development. Clinical Pharmacist publishes Review articles, Perspectives, evidence-based CPD articles and Research articles on topics from drug discovery to clinical pharmacology and pharmacy.

The international audience of Pharmaceutical Journal Publications consists of pharmacists, pharmaceutical scientists and healthcare professionals. The journal is available to 44,000 members of the Royal Pharmaceutical Society, as well as non-member individual subscribers and subscribing institutions.